ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. - Wikidata - wikimedia - TriplyDB

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

http://www.wikidata.org/entity/Q40141542

about

At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone Systemic therapies for pancreatic cancer--the role of pharmacogenetics HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments Embryonic requirements for ErbB signaling in neural crest development and adult pigment pattern formation Treatment of vestibular schwannoma cells with ErbB inhibitors Genetically dependent ERBB3 expression modulates antigen presenting cell function and type 1 diabetes risk.An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation Biological approaches to therapy of pancreatic cancer.ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma ERBB3: Multifunctional enabler or primary actor in pancreatic cancer?Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies Schizophrenia susceptibility genes directly implicated in the life cycles of pathogens: cytomegalovirus, influenza, herpes simplex, rubella, and Toxoplasma gondii.Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells.Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways Collections of simultaneously altered genes as biomarkers of cancer cell drug response The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors.The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1 Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models Biologic therapies for advanced pancreatic cancer.Paeoniflorin Potentiates the Inhibitory Effects of Erlotinib in Pancreatic Cancer Cell Lines by Reducing ErbB3 Phosphorylation EGFR family: structure physiology signalling and therapeutic targets.Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.Challenges of drug resistance in the management of pancreatic cancer.HER3/ErbB3, an emerging cancer therapeutic target.Pertuzumab in gastrointestinal cancer.Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling.Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology.ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.

P2860

Q26866067-3E4A5741-D04A-49F4-AFFF-39B736360212 Q27021716-11569204-8C1D-4374-B44B-BF984627BF3B Q27853067-E73FC1E8-8878-4F5C-95D9-47745180B623 Q27853292-5823CF5B-5043-4112-832A-B2914A64AF7F Q28547357-C483D845-AE32-423B-9569-171A691699BE Q28752378-4842BBEB-120E-4358-B26B-6A50FB589583 Q30458767-A241D358-7EC3-4E2B-8561-71304D15268B Q33644491-233FC402-FDE2-45BB-A006-84D0D22016FF Q33733313-6A299332-1C52-43CD-8AE1-F1C2AB1FB7DB Q33899938-EE5D7630-6CB7-4DB8-AA91-E69528F609D4 Q34582105-9FFD0A29-D0D9-4215-B471-E98443B02933 Q34582111-D11BD838-7E95-4D33-8C7B-A85085D822D4 Q34719632-DE7CEEC2-822D-4F75-AF9B-7EAEFD487089 Q34786420-15E80103-0AF7-49DD-A3BD-7E36426BB287 Q35208054-B7F57D19-DF69-4C05-91C9-3263608E3F9F Q35449387-4CD2F578-81F8-45BF-852F-A51D910B646A Q35571884-3A6B3567-7B6C-4EE6-8146-A0FB02ACF565 Q35584314-F2E8516F-3D72-469F-ACFF-E37472A18183 Q35682599-6E33717C-0F8E-45C6-808C-D3D3C791A213 Q35820920-DA758AAB-FB46-43CC-971E-0A1C2B914B80 Q35836035-4B4866FA-BEBF-4161-B326-D83C691C2A91 Q36230591-2384D17D-DB65-4413-8300-506655BB6A51 Q36410371-597016B1-70A7-4BEB-9FFF-10083422AAB5 Q36466104-52C3C0DD-57A3-49B0-9F7B-A863C717CCC3 Q36698868-E74C294D-F0C4-422A-B3B4-5DDC0CD02A23 Q36839141-B218840F-51ED-4B72-887D-B7905182B54C Q36851569-E5C26B80-4611-4270-BC51-CD7F0FA46FC6 Q37009828-81A754ED-9831-4747-BE6D-4B5D35C0A58A Q37237126-389B9B0F-9E54-4B4D-B5E3-8CC83C687F43 Q37242685-B56F517B-D7A3-49CA-A67C-892DABB5FDE7 Q37243523-207E3C09-15F8-46C4-B547-D82024D9EDC8 Q37272623-5E78C383-3DF5-4909-BA69-A3AA04B90F81 Q37536346-0D877B8A-EBDA-40B8-9E82-2112A80D1B8F Q37799830-F077F178-0578-4C63-B24D-9D068782F911 Q38615197-855113EE-ABF1-4E27-BD6E-C9EAB0A828FC Q38653309-27F7BDE7-945E-4E8A-A785-C5A97B2EC74E Q38766765-929B8593-EB9C-4CC1-A6D8-9E23C00DF252 Q38869420-ADD02FF4-90BD-4627-8C0C-A7C2F5A79BD4 Q39206148-DB207F41-73A5-4E8B-8CB6-1E33DB270A67 Q39533928-B42D10F3-7A46-4D5F-B821-714E2A2F899A

P2860

ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.

http://www.wikidata.org/entity/Q40141542

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

ErbB3 expression and dimerizat ...... cell sensitivity to erlotinib.

@en

type

label

ErbB3 expression and dimerizat ...... cell sensitivity to erlotinib.

@en

prefLabel

ErbB3 expression and dimerizat ...... cell sensitivity to erlotinib.

@en

P1433

Q40141542-DDB4C505-A7F1-4BD1-BA70-FF5E574A26C5

P1476

Q40141542-DE3F0602-53AA-4EF4-AA5C-BA7E69F6E6AF

P2093

Q40141542-097D24BC-E32C-4357-8F2B-98E5C518E1E7

Q40141542-11A15D01-3BC1-44E7-A09F-C3ABD1A05481

Q40141542-193D0FDC-5596-49D8-A88D-AEBFF07DBE00

Q40141542-7663E5DE-964B-4548-AAE8-BE83C8DBEB7A

Q40141542-896B4A4F-8C97-4A83-B82A-B6F79D3F9542

Q40141542-974CB369-625E-4D8E-B941-4E833B55577D

Q40141542-A33A77C3-C13D-4FAF-B5B9-E17A4A7FB5B1

Q40141542-A62433F9-B06A-4532-9910-F325D96B69DF

Q40141542-B2D65934-C152-4861-9406-CE9EA2C34EC9

P304

Q40141542-6532B448-2B17-4062-B9F7-84D4113B37D0

P31

Q40141542-9B1818A3-1452-4544-9E06-D9127019FA40

P356

Q40141542-C84FA151-87B9-4A44-B0CF-0134388DB972

P433

Q40141542-A6C3E8DC-A3CC-43D7-A827-B0561C55B001

P478

Q40141542-DA6CA519-0379-4CF2-826F-E808BDE0900D

P50

Q40141542-C951E61B-55DE-4A55-AEAE-6D7AF8DB84A0

P577

Q40141542-4368F0FF-BDFB-4B5D-8987-1F2EE535CD4F

P5875

Q40141542-595C60D7-0B6F-4945-BCA3-09441686A625

P698

Q40141542-F730091A-884B-46A8-8871-E076080BE0BA

P356

P1433

Cancer Biology and Therapy

P1476

ErbB3 expression and dimerizat ...... cell sensitivity to erlotinib

@en

P2093

Andrey Frolov

http://www.w3.org/2001/XMLSchema#string

Brandon C Ku

http://www.w3.org/2001/XMLSchema#string

Ching-Wei D Tzeng

http://www.w3.org/2001/XMLSchema#string

Emily E Cannon

http://www.w3.org/2001/XMLSchema#string

J Harrison Howard

http://www.w3.org/2001/XMLSchema#string

J Pablo Arnoletti

http://www.w3.org/2001/XMLSchema#string

Kyle Schuller

http://www.w3.org/2001/XMLSchema#string

Martin J Heslin

http://www.w3.org/2001/XMLSchema#string

Selwyn M Vickers

http://www.w3.org/2001/XMLSchema#string

P304

548-554

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.6.4.3849

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Donald J Buchsbaum

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6372273

http://www.w3.org/2001/XMLSchema#string

P698

17457047

http://www.w3.org/2001/XMLSchema#string